Clinical Trial

Bariatric Surgery and Pharmacokinetics of Escitalopram

Recruiting
View on ClinicalTrials.gov →
Summary
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on escitalopram are investigated.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-03-04; most recent amendment 2023-03-24.
Trial Details
NCT Number NCT03460379
Lead Sponsor Norwegian University of Science and Technology
Collaborators: St. Olavs Hospital, Volvat Medisinsk Senter Stokkan, Namsos Hospital, Alesund Hospital
Conditions Obesity, Morbid
Enrollment 12 participants
Start Date 2016-11-02
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2023-03-27